Vanguard Group
OTLK icon

Vanguard Group’s Outlook Therapeutics OTLK Stock Holding History

Vanguard Group’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.31M Buy
1,465,167
+122,540
+9% +$196K ﹤0.01% 3516
2025
Q3 		$1.42M Buy
1,342,627
+91,029
+7% +$157K ﹤0.01% 3676
2025
Q2 		$2M Buy
1,251,598
+414,191
+49% +$660K ﹤0.01% 3531
2025
Q1 		$1.02M Sell
837,407
-15,133
-2% -$26.5K ﹤0.01% 3703
2024
Q4 		$1.61M Sell
852,540
-3,336
-0.4% -$13.7K ﹤0.01% 3629
2024
Q3 		$4.57M Buy
855,876
+308,103
+56% +$2.25M ﹤0.01% 3302
2024
Q2 		$4.04M Buy
547,773
+206,473
+60% +$1.66M ﹤0.01% 3345
2024
Q1 		$4.08M Buy
341,300
+13,280
+4% +$107K ﹤0.01% 3378
2023
Q4 		$2.58M Buy
328,020
+13,866
+4% +$117K ﹤0.01% 3511
2023
Q3 		$1.39M Buy
314,154
+6,748
+2% +$149K ﹤0.01% 3723
2023
Q2 		$10.7M Buy
307,406
+6,879
+2% +$188K ﹤0.01% 2910
2023
Q1 		$6.55M Buy
300,527
+17,394
+6% +$389K ﹤0.01% 3179
2022
Q4 		$6.12M Buy
283,133
+2,263
+0.8% +$49.2K ﹤0.01% 3209
2022
Q3 		$6.85M Sell
280,870
-112
-0% -$2.6K ﹤0.01% 3139
2022
Q2 		$5.73M Sell
280,982
-824
-0.3% -$23.7K ﹤0.01% 3303
2022
Q1 		$10M Sell
281,806
-16,556
-6% -$517K ﹤0.01% 3152
2021
Q4 		$8.12M Buy
298,362
+61,353
+26% +$2.19M ﹤0.01% 3340
2021
Q3 		$10.3M Buy
237,009
+5,288
+2% +$255K ﹤0.01% 3224
2021
Q2 		$11.5M Buy
231,721
+23,457
+11% +$1.09M ﹤0.01% 3127
2021
Q1 		$9.37M Buy
208,264
+91,782
+79% +$3.51M ﹤0.01% 3181
2020
Q4 		$3.03M Buy
116,482
+82,650
+244% +$1.73M ﹤0.01% 3554
2020
Q3 		$487K Buy
33,832
+7,019
+26% +$156K ﹤0.01% 3824
2020
Q2 		$692K Buy
26,813
+354
+1% +$6.31K ﹤0.01% 3697
2020
Q1 		$318K Buy
26,459
+10,621
+67% +$176K ﹤0.01% 3775
2019
Q4 		$187K Sell
15,838
-8
-0.1% -$186 ﹤0.01% 3952
2019
Q3 		$472K Sell
15,846
-3,954
-20% -$153K ﹤0.01% 3832
2019
Q2 		$824K Buy
19,800
+17,362
+712% +$809K ﹤0.01% 3729
2019
Q1 		$361K Buy
2,438
+8
+0.3% +$1.13K ﹤0.01% 3826
2018
Q4 		$194K Sell
2,430
-1,150
-32% -$141K ﹤0.01% 3909
2018
Q3 		$561K Buy
3,580
+1,649
+85% +$232K ﹤0.01% 3828
2018
Q2 		$261K Sell
1,931
-23
-1% -$3.39K ﹤0.01% 3937
2018
Q1 		$278K Buy
1,954
+46
+2% +$8.22K ﹤0.01% 3907
2017
Q4 		$397K Hold
1,908
– – ﹤0.01% 3798
2017
Q3 		$418K Buy
1,908
+141
+8% +$25.6K ﹤0.01% 3783
2017
Q2 		$285K Hold
1,767
– – ﹤0.01% 3836
2017
Q1 		$757K Buy
1,767
+22
+1% +$10.9K ﹤0.01% 3652
2016
Q4 		$841K Buy
1,745
+1,163
+200% +$651K ﹤0.01% 3611
2016
Q3 		$396K Buy
+582
New +$370K ﹤0.01% 3798

Other funds holding OTLK

SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Vanguard Group's OTLK Position: Q4 2025 in Review

Vanguard Group increased its Outlook Therapeutics (OTLK) stake by 9.1% in Q4 2025, buying an estimated $196K and bringing the position to 1,465,167 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3516.

Vanguard Group first reported a position in OTLK in Q3 2016 and has held it in 38 quarters since. The position peaked at $11.5M in Q2 2021. 53 funds tracked by Wall St. Rank hold OTLK as of Q4 2025.

  • Vanguard Group held 1,465,167 shares of Outlook Therapeutics worth $2.31M as of Q4 2025.
  • Vanguard Group bought 122,540 Outlook Therapeutics shares in Q4 2025, an estimated $196K.
  • Outlook Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3516 holding.
  • Vanguard Group first reported a position in Outlook Therapeutics in Q3 2016 and has held it in 38 quarters since.
  • Vanguard Group's Outlook Therapeutics position peaked at $11.5M in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.